Online inquiry

IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14699MR)

This product GTTS-WQ14699MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Sickle Cell Disease (SCD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ14699MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13414MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRO132365
GTTS-WQ12925MR IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PankoMab
GTTS-WQ9845MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ12716MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA OMP-305B83
GTTS-WQ63MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ5363MR IVTScrip™ mRNA-Anti-env, CD4(178) PE40(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CD4(178) PE40
GTTS-WQ3037MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ13523MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW